Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Baxter Ready For Full-Scale Production of A (H1N1) Vaccine
Baxter has announced that it has completed testing and evaluation of the A (H1N1) influenza virus, and is now in full-scale production stage using its Vero cell culture
Baxter has announced that it has completed testing and evaluation of the A (H1N1) influenza virus, and is now in full-scale production stage using its Vero cell culture
Philadelphia-based Hemispherx has announced that its collaborative influenza vaccine development partner in Japan, Biken, has decided to expand its Flu production capacity. “Biken decided to expand its manufacturing
Bayer Schering Pharma has completed its first global phase-II study analyzing the sensitivity and specificity of BAY 94-9172 (AV1/ZK). The study used positron emission tomography (PET) in patients
Abraxis Bioscience has launched Abraxane for Injectable Suspension in China, for the treatment of patients with metastatic breast cancer. In a global phase-III clinical trial, and in phase-II
Sanofi Pasteur, the vaccines division of Sanofi-Aventis, has announced that it is ready to support public health efforts to tackle the emergence of the new A(H1N1) influenza strain.
With WHO raising the current level of influenza pandemic alert from phase 5 to phase 6, GSK has initiated development of a new candidate vaccine for A (H1N1)
Novartis has produced its first batch of experimental swine flu vaccine. Swine flu was declared pandemic by WHO on Thursday, June 11, 2009. The vaccine was produced at
Bristol-Myers Squibb has announced the results of two Orencia (abatacept) studies at the 2009 Annual European Congress of Rheumatology (EULAR), in Copenhagen, Denmark. Orencia is a selective co-stimulation
CombinatoRx has announced the full data on Synavive (CRx-102) phase-II knee osteoarthritis (OA) trial (COMET-1). Synavive, a dissociated glucocorticoid and prednisolone, provided safe and effective pain relief in
VIA Pharmaceuticals has met FDA for its lead drug, VIA-2291 (atreleuton). The company has reviewed safety and biologic activity data from the Via-2291 phase 2 CEA and ACS